

# 2019 Influenza B virus Infections R&D Pipeline Drugs, Companies, Trials and Developments

https://marketpublishers.com/r/244444FF44EEN.html

Date: March 2019

Pages: 95

Price: US\$ 2,199.00 (Single User License)

ID: 244444FF44EEN

### **Abstracts**

The global demand for Influenza B virus Infections treatment options is expected to report strong growth over the medium to long term future driven by consumption in major markets. Strong growth prospects of drugs for Influenza B virus Infections are driving leading companies to invest their resources on the pipeline.

Companies quickly advancing their drug candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Influenza B virus Infections pipeline companies from advancing their products.

Influenza B virus Infections Report Description

The H1-2019 pipeline review report on Influenza B virus Infections is a comprehensive study on drug candidates across different phases worldwide. This report evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date.

The Influenza B virus Infections pipeline guide presents information on all active drugs currently being developed for Influenza B virus Infections. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Influenza B virus Infections pipeline candidate are analyzed.

Further, current phase of development, mechanism of action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Influenza B virus Infections drug candidates.



Drug development companies, collaborators, originating companies, license providers and universities participating in the Influenza B virus Infections product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Influenza B virus Infections pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed the report based on robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Influenza B virus Infections pipeline report includes-

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, , Phase, Co Developer, Originator, Synonym, Orphan Drug Status, Type of Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials



### **REASONS TO BUY**

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Influenza B virus Infections pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Influenza B virus Infections pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Influenza B virus Infections pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.



### **Contents**

### **GLOBAL INFLUENZA B VIRUS INFECTIONS PIPELINE OVERVIEW**

Key Findings, 2019
Disease Overview
Report Guide and Research Methodology

### **EXECUTIVE SUMMARY**

Influenza B virus Infections Drugs under active development, H1@2019 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)

Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration) Companies involved in Influenza B virus Infections pipeline, H1@2019 Mechanism of Action wise Influenza B virus Infections Pipeline Candidates

### ABBVIE INC INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

**Drug Mechanism of Action** 

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### ADIMMUNE CORP INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 



Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

**Drug Mechanism of Action** 

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### ALTRAVAX INC INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### AMARILLO BIOSCIENCES INC INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation



Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

**Drug Mechanism of Action** 

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### APHIOS CORP INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

**Drug Mechanism of Action** 

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### ASTRAZENECA PLC INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

**Drug Mechanism of Action** 



### Clinical/Pre-clinical Trial Details Latest Drug Developments

### **AUSBIO LTD INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS**

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

**Drug Mechanism of Action** 

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### **BIOTRON LTD INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS**

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### COCRYSTAL PHARMA INC INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS



**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### CONTRAFECT CORP INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### DAIICHI SANKYO CO LTD INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer



Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### **EVOTEC AG INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS**

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### GC PHARMA INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 



Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

### GLAXOSMITHKLINE PLC INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

**Drug Mechanism of Action** 

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### INOVIO PHARMACEUTICALS INC INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments



### IQUR LTD INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### MEDICAGO INC INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### MEDIMMUNE LLC INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 



**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

**Drug Mechanism of Action** 

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### NOVAVAX INC INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

**Drug Mechanism of Action** 

Clinical/Pre-clinical Trial Details

Latest Drug Developments

## ROMARK LABORATORIES LC INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration



Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### SANOFI INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### SANOFI PASTEUR SA INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 



Drug Mechanism of Action Clinical/Pre-clinical Trial Details Latest Drug Developments

### SEQIRUS LTD INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### SHIONOGI & CO LTD INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### SK BIOSCIENCE INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS



**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

**Drug Mechanism of Action** 

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### VACTHERA BIOTECH GMBH INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### **VAXART INC INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS**

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 



Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

**Drug Mechanism of Action** 

Clinical/Pre-clinical Trial Details

Latest Drug Developments

### VIRAMATIX SDN BHD INFLUENZA B VIRUS INFECTIONS PIPELINE DETAILS

**Business Profile** 

**Drug Details** 

**Drug Snapshot** 

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

**Current Status** 

**Drug Overview** 

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

# LATEST INFLUENZA B VIRUS INFECTIONS DRUG PIPELINE DEVELOPMENTS, 2019

### **APPENDIX**

About Us

Sources and Methodology

**Contact Information** 



### I would like to order

Product name: 2019 Influenza B virus Infections R&D Pipeline Drugs, Companies, Trials and

Developments

Product link: <a href="https://marketpublishers.com/r/244444FF44EEN.html">https://marketpublishers.com/r/244444FF44EEN.html</a>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

### **Payment**

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/244444FF44EEN.html">https://marketpublishers.com/r/244444FF44EEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Lastasass	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



